Orally inhaled heparin in patients with cystic fibrosis (CF)

This trial is testing whether inhaled heparin — a medication more commonly used to prevent blood clots — can help people with cystic fibrosis (CF) breathe more easily and have fewer infections. Cystic fibrosis causes thick, sticky mucus to build up in the lungs, leading to repeated infections and lung damage. Heparin inhaled as a mist may help thin the mucus and reduce inflammation in the airways. You may be eligible if: - You are 16 years or older - You are a non-smoker - You have a confirmed diagnosis of cystic fibrosis with lung disease - Your lung function (FEV1) is between 40% and 90% of normal for your age and height - You regularly produce mucus and can cough it up - You are using adequate contraception if you could become pregnant You may NOT be eligible if: - You have a known contraindication to heparin (e.g., history of heparin-induced low platelets, bleeding disorder) - You have significant liver disease or signs of portal hypertension - You are pregnant or breastfeeding - You have had or are planning major chest surgery during the trial - You have a current diagnosis of aspergilloma (a type of fungal lung infection) - You are taking regular blood-thinning medication like warfarin or aspirin Talk to your doctor about whether this trial might be right for you.